An FDA advisory committee yesterday voted 13-1 to support the use of Novartis' (NVS +0.85%)...

|About: Novartis AG (NVS)|By:, SA News Editor

An FDA advisory committee yesterday voted 13-1 to support the use of Novartis' (NVS +0.85%) tobramycin inhalation powder for patients with cystic fibrosis and whose lungs contain bacteria called Pseudomonas aeruginosa. The antibiotic powder would be more convenient than Novartis older version of tobramycin, which requires a nebulizer machine.